This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Methods of producing N,N-dimethyl sulfamoyl fluoride and related derivatives of the formula FS(O).sub.2NR.sub.2 (I) by contacting a sulfamoyl nonfluorohalide compound of the formula XS(O).sub.2NR.sub.2 (II) with anhydrous hydrogen fluoride under conditions sufficient to produce the N,N-dimethyl sulfamoyl fluoride or derivative thereof of Formula I, wherein R in each of Formulas I and II is, independently, a linear or branched alkyl, alkenyl, or alkynyl group containing 1 to 12 carbon atoms, the Rs can be joined to form a cyclic amine with the N, and X is any one of chlorine, bromine, and iodine.

Methods of producing N,N-dimethyl sulfamoyl fluoride and related derivatives of the formula FS(O).sub.2NR.sub.2 (I) by contacting a sulfamoyl nonfluorohalide compound of the formula XS(O).sub.2NR.sub.2 (II) with anhydrous hydrogen fluoride under conditions sufficient to produce the N,N-dimethyl sulfamoyl fluoride or derivative thereof of Formula I, wherein R in each of Formulas I and II is, independently, a linear or branched alkyl, alkenyl, or alkynyl group containing 1 to 12 carbon atoms, the Rs can be joined to form a cyclic amine with the N, and X is any one of chlorine, bromine, and iodine.

Methods of producing N,N-dimethyl sulfamoyl fluoride and related derivatives of the formula FS(O).sub.2NR.sub.2 (I) by contacting a sulfamoyl nonfluorohalide compound of the formula XS(O).sub.2NR.sub.2 (II) with anhydrous hydrogen fluoride under conditions sufficient to produce the N,N-dimethyl sulfamoyl fluoride or derivative thereof of Formula I, wherein R in each of Formulas I and II is, independently, a linear or branched alkyl, alkenyl, or alkynyl group containing 1 to 12 carbon atoms, the Rs can be joined to form a cyclic amine with the N, and X is any one of chlorine, bromine, and iodine.

The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at 30 C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50 C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises a non-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound.

Si(R.sup.1).sub.a(R.sup.2).sub.4-a(1)

##STR00001##

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

The present disclosure provides a chlorhexidine-cyclamate complex having a formula [C.sub.22H.sub.32Cl.sub.2N.sub.10][C.sub.6H.sub.12NO.sub.3S].sub.2 having antibacterial and antiplaque properties, together with oral care compositions comprising the complex, and methods of making and using these complexes and compositions.

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.